The National Institute for Health and Clinical Excellence (NICE) has published final guidance recommending ocriplasmin (Jetrea, ThromboGenics) as an option for treating some people with the rare eye condition, vitreomacular traction.
Vitreomacular traction occurs when the vitreous, the gel-like substance in the eye, pulls abnormally on the retina, the light-sensitive layer of tissue at the back of the inner eye, which is responsible for processing visual images. The pulling of the gel disturbs the retina, causing swelling and distorted vision, and sometimes a hole in the macular area. It can occur as a result of ageing.
NICE has recommended ocriplasmin as an option for treating vitreomacular traction in adults, only if an epiretinal membrane is not presenti, and they have a stage II macular holeii (full thickness with a diameter of 400 micrometres or less) and/or they have severe symptoms.
Professor Carole Longson, Health Technology Evaluation Centre Director at NICE said: “Vitreomacular traction is a serious eye condition, which can lead to loss of vision in the long run. Ocriplasmin injection represents a new and welcome option for patients with this condition and their clinicians, as it provides an alternative to ‘watch and wait’ and/or surgery. NICE is pleased to recommend ocriplasmin as an option for this condition in final guidance.”